aurinia buyout rumors
by The Fold, Keep your ear to the ground with our FREE newsletter including our watch list, weekly review and daily updates. A place to discuss Aurinia Pharmaceuticals, Inc. Press J to jump to the feed. Glenn Newberry in an earlier post today was asking whether Benlysta from GlaxoSmithKline (GSK), being trialled for lupus nephritis, poses any threat to Aurinia (AUPH). Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights. var CONTENT_ID = 'everything'; Do you want real-time, actionable news delivered to your inbox? A buyout … Major price movers (stocks priced > $1.00, volume > 50k): Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume. Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) announced after hours that it intends to reduce its workforce by 30% and potentially reduce the target enrolment of its Phase 3 URIROX-2 trial in patients with Enteric Hyperoxaluria, which might result in earlier interim analysis. Mar 9, 2021 • 1:00pm EST . Notify me of follow-up comments by email. 2 Top Biotech Buyout Candidates Amarin and Aurinia will probably be bought out before the end of 2020. Movers; Street Research. Shares, which closed normal trading hours down 15%, are currently down a further 6% after hours to $6.44. Hosts a Panel on Reimbursement and Pricing – Pre- and Post-Commercialization Considerations. Moving forward, the CNA Finance team will be keeping a close eye on AUPH. Kodiak Sciences Inc. (NASDAQ:KOD) shares closed up 49% to $73.41. })(); As mentioned above, Aurinia Pharmaceuticals is having a relatively strong day in the market today. Ardelyx, Inc. (NASDAQ:ARDX) announced after hours it has commenced an underwritten public offering of up to $80m of shares of its common stock. Akebia is a lot like other small biotech companies with quality management teams executing well but ignored by investors for reasons that don't really make much sense fundamentally. Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences Business Wire - 3/2/2021 6:05:00 AM: Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 2/24/2021 4:30:29 PM Annual Report (10-k) Edgar (US Regulatory) - 2/24/2021 4:14:34 PM Aurinia Pharma EPS beats by $0.15, beats on revenue Seeking Alpha - 2/24/2021 4:07:13 PM Look up "Buy the rumor, sell the news." Phase 3 interim analysis due 2Q/3Q 2022 and top-line data late-2022 or early-2023. DOW 0.00%. February 24, 2021. Phase 1/2 interim data presented December 4, 2019. Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Secondary endpoints also achieved statistical significance in favor of voclosporin. User account menu. save. Benlysta is a monoclonal antibody that binds to and inhibits BAFF (B-cell activating factor). Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences . The price run up actually happened prior to the actual news. As soon as they did, the CNA Finance team started to work to uncover the reason for the movement. '